Ucbbiopharma Srl

Ucb Pharma, S.a.

Ucb Biopharma Sprl

Emma Dave

David Paul Humphreys

Sam Philip Heywood

Laura Griffin

Pallavi Bhatta

Ralph Adams

Daniel John Lightwood

Diane Marshall

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of a) a polypeptide chain of formula (I): VH—CH—X—V; and b) a polypeptide chain of formula (II): VL-CL-Y—Vand pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.

Multispecific antibody constructs

The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab' fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.

Dual specificity antibody fusions

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I):(Vxx)Vx-Cx-X-V; and b) a polypeptide chain of formula (II): (Vyy)Vy-Cc) a polypeptide of formula (III):Vwherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, Vrepresents a variable domain,independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between Vand V, in particular where a disulphide bond is present. The disclosure also extends to pharmaceutical formulation comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure further extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.

Single linker FabFv antibodies and methods of producing same

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of: a) a polypeptide chain of formula (I): VH&#x2014;CH&#x2014;X&#x2014;V; and b) a polypeptide chain of formula (II): VL-CL-Y&#x2014;Vand pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.

The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Antibody molecules which bind TNF alpha

The present disclosure relates to a multi-specific antibody molecule comprising or consisting of three polypeptides: a) a polypeptide chain of formula (I): (Vxx)Vx-Cx-X-V; and b) a polypeptide chain of formula (II): (Vyy)Vy-Cy c) a polypeptide of formula (III): Vwherein Vx represents a variable domain, Vxx represents a variable domain, Cx represents a constant region, X represents a linker, V represents a variable domain, Vy represents a variable domain, Vyy represents a variable domain, Cy represents a constant region, Vrepresents a variable domain,independently represents 0 or 1, wherein the polypeptide chain of formula (I) and the polypeptide chain of formula (II) is aligned such that the constant regions Cx and Cy are paired and the variable domains Vx and Vy are paired to form a binding domain and optionally a disulphide bond is present between V and V, in particular where a disulphide bond is present. The disclosure also extends to pharmaceutical formulation comprising the construct, DNA encoding the constructs and vectors comprising same. The disclosure further extends to a method of expressing the constructs, for example in a host cell and methods for formulating same as a pharmaceutical composition. The disclosure also relates to use of the constructs and formulations in treatment.

The present invention provides a multivalent antibody or a heavy/light chain component thereof comprising: a heavy chain comprising a constant region fragment, said constant region fragment located between two variable domains which are not a cognate pair, the heavy chain further comprising an Fc region with at least one domain selected from CH2, CH3 and combinations thereof, with the proviso that the heavy chain contains no more than one CH1 domain and only contains two variable domains, and a light chain comprising a constant region fragment located between two variable domains which are not a cognate pair, wherein said heavy and light chains are aligned to provide a first binding site formed by a first cognate pair of variable domains and a second binding site formed by a second cognate pair of variable domains.

Multivalent antibodies

The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab' fragment with specificity for an antigen of interest, the fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.

Growing community of inventors

Slough, United Kingdom

Emma Dave